The recommended dosage range for WAKIX is 17.8 mg to 35.6 mg taken once daily in the morning upon wakening

  • WAKIX is available in two tablet strengths: 4.45 mg and 17.8 mg
Individually Titrate WAKIX to the 
Effective Dosage*
1

Initiate at 8.9 mg
Two 4.45-mg tablets 
once daily

2

Increase to 17.8 mg
One 17.8-mg tablet 
once daily

3

May increase to 35.6 mg
Two 17.8-mg tablets 
once daily

Recommended titration schedule. Not all patients respond equally to WAKIX.

Maximum recommended dosage.

  • Dose may be adjusted based on tolerability

Dosage modifications are recommended for patients:

  • With moderate hepatic impairment
  • With moderate or severe renal impairment
  • Known to be poor CYP2D6 metabolizers
  • Receiving concomitant strong CYP2D6 inhibitors or strong CYP3A4 inducers

See Full Prescribing Information for recommended dosage and titration.

WAKIX Dosing and Titration

Watch this video to understand the recommended dosing and titration for WAKIX, dosage modifications for specific patient populations, and information to help set patient expectations.

WAKIX Dosing video
WAKIX Dosing with other medications interactive tool

Dosing WAKIX With Other Medications

Some medications have clinically important drug interactions with WAKIX. Identify recommendations for dosing WAKIX with other medications.

Access tool »

The Pharmacokinetic (PK) Profile of WAKIX Supports
Once-Daily Dosing

  • Median t½ ~20 hours (7.5 to 24.2 hours) after a single 35.6-mg dose
  • Median Tmax 3.5 hours (2 to 5 hours)
  • No clinically significant PK differences were observed following administration with a high-fat meal

WAKIX had no clinically important PK interactions with modafinil or sodium oxybate

  • In a clinical PK study to evaluate the concomitant use of WAKIX with modafinil or sodium oxybate, WAKIX had no effect on the PK of modafinil or sodium oxybate, and these agents had no clinically relevant effect on the PK of WAKIX
Effect of WAKIX on
 the PK of Modafinil1,*
Effect of WAKIX on the PK of Modafinil graph
Effect of WAKIX on
 the PK of Sodium Oxybate1,†
Effect of WAKIX on the PK of Sodium Oxybate graph

*Seventeen healthy male subjects received treatment with a single dose of 35.6 mg WAKIX on Day 1, modafinil 200 mg/day from Day 5 to Day 25, and a single dose of 35.6 mg WAKIX plus 200 mg modafinil on Day 26.1 †Sixteen healthy male subjects were randomized 1:1 to one of two treatment sequences: Treatment A (35.6 mg WAKIX) then Treatment B (sodium oxybate [two 2.25-g doses administered 3 hours apart] on Day 1, 35.6 mg WAKIX on Day 2, sodium oxybate [two 2.25-g doses administered 3 hours apart] on Day 3) or Treatment B then Treatment A. Treatment A and Treatment B were separated by 1 week.1

Effect of Modafinil on
 the PK of WAKIX1,*
Effect of Modafinil on the PK of WAKIX graph
Effect of Sodium Oxybate on
 the PK of WAKIX1,†
Effect of Sodium Oxybate on the PK of WAKIX graph

*Seventeen healthy male subjects received treatment with a single dose of 35.6 mg WAKIX on Day 1, modafinil 200 mg/day from Day 5 to Day 25, and a single dose of 35.6 mg WAKIX plus 200 mg modafinil on Day 26.1 †Sixteen healthy male subjects were randomized 1:1 to one of two treatment sequences: Treatment A (35.6 mg WAKIX) then Treatment B (sodium oxybate [two 2.25-g doses administered 3 hours apart] on Day 1, 35.6 mg WAKIX on Day 2, sodium oxybate [two 2.25-g doses administered 3 hours apart] on Day 3) or Treatment B then Treatment A. Treatment A and Treatment B were separated by 1 week.1

Some medications have clinically important drug interactions with WAKIX

Medications That Have Clinically 
Important Drug Interactions With WAKIX
Effect of Other Drugs on WAKIX
Strong CYP2D6 Inhibitors
  • Concomitant administration of WAKIX with strong CYP2D6 inhibitors increases pitolisant 
    exposure by 2.2-fold
Strong CYP3A4 Inducers
  • Concomitant use of WAKIX with strong CYP3A4 inducers decreases exposure of pitolisant exposure by 50%
Histamine 1 (H1) Antagonists
  • WAKIX increases the levels of histamine in the brain; therefore, H1 receptor antagonists that cross the blood-brain barrier may reduce the effectiveness of WAKIX
QT Interval Prolongation
  • Concomitant use of drugs that prolong the QT interval may add to the QT effects of WAKIX and increase the risk of cardiac arrhythmia
Effect of WAKIX on Other Drugs
Sensitive CYP3A4 Substrates
  • WAKIX is a borderline/weak inducer of CYP3A4; therefore, reduced effectiveness of sensitive CYP3A4 substrates may occur when used concomitantly with WAKIX
  • The effectiveness of hormonal contraceptives (e.g., ethinyl estradiol) may be reduced when used with WAKIX and effectiveness may be reduced for 21 days after discontinuation of therapy

See more information about these drug interactions with WAKIX »

WAKIX Dosing Overview in-office resource

WAKIX Dosing 
Overview

Understand the recommended dosing and titration for WAKIX as well as how to set patient expectations about WAKIX.

Download »